Biological therapies for asthma
Five to 10% of asthma patients remain symptomatic and/or have asthma attacks despite adequate inhaled and systemic therapy. Eosinophilic, type 2 airway inflammation is seen in half of these patients with severe asthma. There is now convincing evidence that type 2 inflammation drives susceptibility t...
| Κύριοι συγγραφείς: | , |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Book section |
| Γλώσσα: | English |
| Έκδοση: |
Elsevier
2021
|
| Περίληψη: | Five to 10% of asthma patients remain symptomatic and/or have asthma attacks despite adequate inhaled and systemic therapy. Eosinophilic, type 2 airway inflammation is seen in half of these patients with severe asthma. There is now convincing evidence that type 2 inflammation drives susceptibility to asthma attacks and is associated with a good response to biological therapies. Monoclonal antibodies targeting immunoglobulin E, interleukin (IL)-5 and IL-4/13 now have established efficacy in severe type 2 asthma. Novel alarmin-blocking and crystal-dissolving therapies are promising. Prescribing biologics, weaning steroids and treating subsequent exacerbations are rapidly evolving clinical challenges. |
|---|